NBF introduced its Hall of Fame in 2007 recognizing a prestigious and select group of NBF grant recipients who leveraged their early-career grant funding into successful careers in transfusion medicine, cellular therapies, or patient blood management and who demonstrated exemplary leadership within the field.
This important recognition was reinstated annually in 2015 inducting one to three new members each year that meet the following criteria:
Senior Director Diagnostic Hematology
Director Platelet & Neutrophil Immunology Lab
Senior Investigator, Blood Research Institute
“NBF funding helped finance my early research studies that led to publications, name recognition in the field, and a cascade of career advancing opportunities.”
NBF Grant Year: 1995
NBF Research Project Title: “Role of ABO Blood Group Incompatibility in the Pathogenesis of Neonatal Alloimmune Thrombocytopenic Purpura”
NBF Grant Led To: practical methods for detecting high expression of A and B antigens on the platelets of certain individuals and sparked the development of methods for rare antigen determination. Such testing is today combined with other test results to aid in the diagnosis of difficult cases of fetal and neonatal alloimmune thrombocytopenia.
Dr. Curtis obtained his undergraduate degree in biology from Iowa State University, MS in Transfusion Medicine Science from Marquette, and Ph.D. in Health Sciences and Immunology from the University of Wisconsin-Milwaukee. He also holds board certifications in medical technology, blood banking, and immunology.
Currently, he provides management and scientific direction to several of Versiti’s diagnostic labs as Senior Director of Diagnostic Hematology. In addition, he holds appointments of Senior Investigator at the Blood Research Institute, and Assistant Adjunct Professor at the CTSI, Medical College of Wisconsin.
Work in Dr. Curtis’ laboratory has led to improved methods for detecting pathogenic platelet and neutrophil antibodies and to better understanding of the blood disorders in which they are involved. Recent work led to the molecular characterization of a neutrophil antigen designated HNA-3a, a common target for antibodies that cause transfusion-related acute lung injury (TRALI) – a serious complication of blood transfusion.
Dr. Curtis serves on several national and international committees, journal editorial boards, and is an invited speaker at numerous national and international meetings. He has published over 120 scientific journal articles, and numerous abstracts, reviews, and book chapters relevant to the field.
Head, Blood-Borne Parasites
Lindsley Kimball Research Institute
New York Blood Center
“Being recognized as an NBF awardee supported my laboratory both financially and professionally. Not only did the grant monies focus my work on parasite biology in a translational research direction but also allowed me to forge strong connections with a collaborative network of transfusion medicine researchers.”
NBF Grant Year: 2007
NBF Research Project Title: “Role of Red Cell Glycophorins in the Invasion of Babesia divergens”
NBF Grant Led To: Fruitful collaborations with industry partners resulting in the development of diagnostic and blood screening assays, in addition to serving as a testing platform for pathogen inactivation strategies.
Dr. Lobo is Head of Laboratory of Blood Borne Parasites and a full Member of the Lindsley Kimball F. Research Institute (LFKRI) at the New York Blood Center and. She has had a long and successful history in molecular parasitology for over 20 years, focusing on parasites, like Plasmodium and Babesia, that can be transmitted by transfusion, and studying potential mitigation strategies of the resultant emerging infectious diseases that are transfusion threats. Her laboratory studies the biology underlying the mechanisms of invasion, intracellular development, multiplication and egress in three intra-erythrocytic parasites- Plasmodium falciparum, Babesia divergens and Babesia microti, using in vitro culture systems and rodent models of disease. The lab’s interest focuses on changes mediated by the parasite to the RBC, with the eventual goal of developing viable interventions including drugs to halt transmission of these pathogens. She has been a PI on a number of both basic research and applied research contracts and have successfully administered the projects (staffing, research protections, budget), collaborated with other researchers, and produced many peer-reviewed publications from each project.
Department of Pathology and Cell Biology
Columbia University Medical Center and New York Presbyterian Hospital
“The NBF award was a critical source of funding at a critical time in my early investigative career. It allowed me to generate the data needed to jumpstart my extramurally-funded research program.”
NBF Grant Year: 2011
NBF Research Project Title: “Effect of Repeat Blood Donation on Atherosclerosis and Cancer Risk in Murine Models”
NBF Grant Led To: A series of investigations culminating in a current double-blind, randomized, clinical trial examining the effects of donor iron deficiency on red blood cell recovery, wellbeing, and neurocognition.
Dr. Hod is Associate Professor with Tenure in the Department of Pathology and Cell Biology of Columbia University Irving Medical Center in New York. Dr. Hod’s translational research interests focus on the red cell storage lesion, donor iron deficiency, and recipient iron overload. He is the New York Hub Principal Investigator for the Recipient Epidemiology and Donor Evaluation Study IV-Pediatric (REDS-IV-P) NIH program, recipient of several research grants from the NIH, and has authored more than 80 peer-reviewed articles on transfusion medicine, clinical pathology, and hematology.
Medical Director, Center for Apheresis, Emory Hospital
Medical Director, Laboratory and Blood Bank, Emory Orthopaedics and Spine Hospital
Center for Transfusion and Cellular Therapies
Emory University School of Medicine
“The NBF grant was the first grant I had written or received. It came at a critical time in my career when I was determining whether it was tenable to choose a career as a physician-scientist in transfusion medicine and in so doing, had a significant impact on my career.”
NBF Grant Year: 2013
NBF Research Project Title: “Characterization of Immunity and Tolerance Following RBC Transfusion”
NBF Grant Led To: New insight into donor and recipient factors that influence the likelihood someone will generate alloantibodies following red blood cell transfusion. This work set the foundation for a variety of studies that have naturally extended from this early work that seek to continue defining key factors that influence the development and consequences of red blood cell alloimmunization.
Dr. Sean Stowell received his MD and PhD degrees from Emory, where he graduated Summa Cum Laude. He then stayed at Emory to obtain clinical training in laboratory and transfusion medicine. In addition to receiving the NBF grant, he received the NIH DP5 Early Career Investigator Award and the Burroughs Wellcome Trust Career Award for Medical Scientists and is currently a principal investigator or project leader on five active NIH grants. His research group has published over 100 papers on topics ranging from host-microbial interactions to key factors that regulate red blood cell alloimmunization. In addition to publishing and lecturing extensively, Sean sits on the editorial board of Transfusion and has been involved in AABB locally and nationally. He is currently an Associate Professor in the Department of Pathology and Laboratory Medicine at the Emory University School of Medicine where he also serves as the Medical Director of the Apheresis Center at Emory University Hospital.
Professor of Pathology and Laboratory Medicine
Director, Blood Bank/Transfusion Medicine
University of Rochester Medical Center
“This NBF funding in 1989 was one of my first extramural grants. It provided validation of our work on transfusion immumomodulation and post-operative infections, which has been central to my career. These NBF studies provided data suggesting that avoiding allogeneic transfusions of red cells improved clinical outcomes.”
NBF Grant Year: 1989
NBF Research Project Title: "Comparison of the Clinical and Immunologic Effects of Autologous or Homologous Blood Transfusions in Patients Undergoing Spinal Fusion Surgery.”
NBF Grant Led To: Confirmation of our previous finding in hip replacement surgery that receipt of any allogeneic red cells was associated with dose dependent increases in post-operative infection, fever, days of antibiotics and length of stay. In contrast autologous transfusions at any dose were not associated with increased post-operative infections, fevers, or length of stay, suggesting that the effects of allogeneic transfusion on post-operative infection were causal and immunologic.
Neil Blumberg, MD recently completed his 40th year at the University of Rochester, where he is Director of the Transfusion Service/Blood Bank and Professor of Laboratory Medicine. His residency training in hematology, blood banking and laboratory medicine was at Yale, where he received his BS and MD degrees. He has had the great good fortune of having a spouse, Dr. Joanna Heal, MRCP, whose training in internal medicine/hematology/oncology complements his own. The two have co-authored papers together on the subjects of platelet transfusion refractoriness, post-transfusion nosocomial infection, immunomodulation, thrombosis and multi-organ failure. This work has provided one of the rationales for patient blood management.
Drs. Blumberg and Heal demonstrated that ABO mismatched transfusions are more toxic than previously realized, likely due to formation of immune complexes. ABO non-identical platelet transfusions are associated with increases in refractoriness, bleeding, organ failure and mortality. Partial mitigation of the adverse effects of transfusions occurs with leukoreduction, ABO matching, restrictive transfusion practices and washing of transfused cells. Their most recent interest is in the toxicity of 0.9% saline and the superiority of balanced solutions for washing of blood cells. Some of the toxicity of stored red cells and saline is due to release of free hemoglobin, heme and iron after transfusion.
Vice President, Research and Scientific Programs
Director, Epidemiology and Health Policy Science
Vitalant Research Institute
Adjunct Professor, Laboratory Medicine
University of California San Francisco
“The NBF funding literally launched my extramurally funded research career, showing me I could successfully obtain grant funding.”
NBF Grant Year: 2005
NBF Research Project Title: “Retrospective Cohort Analysis of Return Behavior in Temporarily Deferred and Eligible Voluntary Blood Donors.”
NBF Grant Led To: Providing insights into the consequences of blood donor selection policies on donor behavior during a time when we must re-focus our efforts on a new generation who will donate blood to meet the supply needs of transfusion recipients.
Brian Custer is the Director of Epidemiology and Health Policy Science and a Vice President of Research and Scientific Programs at Vitalant Research Institute in San Francisco. He is also a Professor in the Department of Laboratory Medicine at the University of California San Francisco and is an affiliate faculty member in the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington, Seattle. He earned his MPH and PhD degrees from the University of Washington in Seattle. He is actively involved in several committees and working groups of AABB, a member of the Transfusion-Transmitted Infectious Diseases Working Party of ISBT, and a leader of the ISBT Academy I TRY IT program. He conducts epidemiology and health outcomes research in blood donors and transfusion recipients, primarily focused on infectious diseases. Dr. Custer is the Principal Investigator of the San Francisco Clinical Site (hub) of the US NIH NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS-IV-P), the Brazil Component of the same program, and the REDS-III program in Brazil. He is also the Principal Investigator for the Laboratory and Risk Factor Coordinating Center of the US Transfusion-Transmissible Infections Monitoring System.
AABB Past President
“Receiving NBF funding was a critical step in my academic career. Through the process I learned how to write a grant, how to successfully and systematically perform studies and publish their results, and about blood donation. I am thankful for the funding support.”
NBF Grant Year: 2008
NBF Research Project Title: “Blood Donation Considerations in African Americans.”
NBF Grant Led To: An improved understanding of blood donation rates, deferral rates, motivators and barriers in African American versus white individuals.
Beth Shaz, MD, is Deputy Director, Marcus Center for Cellular Cures, and Professor of Pathology at Duke University. Prior to Duke University, she was Chief Medical and Scientific Officer, Executive Vice President at New York Blood Center (NYBC). Beth is responsible for all medical and scientific activities throughout the NYBC, including the Lindsey F. Kimball Research Institute, hemophilia services, transfusion services, cellular therapy, perioperative autologous transfusion, and clinical apheresis. Additionally, she is leading NYBC’s Comprehensive Cell Solutions, which is focused on facilitating the next generation of cures in transfusion medicine and cell therapy. Previously, she was an associate professor at Emory School of Medicine and served as transfusion service director at Grady Memorial Hospital and program director for the Center of Transfusion and Cellular Therapies Transfusion Medicine Fellowship. Earlier, she was an instructor at Harvard Medical School and served as associate medical director of the transfusion service and medical director of the transfusion/pheresis unit at Beth Israel Deaconess Medical Center in Boston.
Dr. Shaz is the president of AABB’s Board of Directors. She is a scientific member of Biomedical Excellence for Safer Transfusion, an Associate Editor of TRANSFUSION and an editorial board member of BLOOD. She received her medical degree from University of Michigan Medical School and a Bachelor of Science degree in chemical engineering from Cornell University.
Provost, Rutgers Biomedical Health Science, New Brunswick
Distinguished Professor of Medicine,
Richard C. Reynolds, M.D., Chair, General Internal Medicine,
Rutgers Robert Wood Johnson Medical School
“NBF funding was one of the first national competitive peer reviewed research grants that I was awarded and it contributed significantly to establishing me as an independent investigator in transfusion medicine.”
NBF Grant Year: 1993
NBF Research Project Title: “Cost Effectiveness of Autologous Blood Transfusion.”
NBF Project Led To: An evaluation of the cost effectiveness of autologous transfusion and demonstrated that it would not be cost effective unless risk of bacterial infection associated with transfusion was elevated.
Dr. Jeffrey Carson is the Provost, New Brunswick at Rutgers Biomedical Health Science, Distinguished Professor of Medicine, and the Richard C. Reynolds, M.D. Chair in General Internal Medicine at Rutgers Robert Wood Johnson Medical School. He received his research training at the University of Pennsylvania and was a Fogarty Senior International Fellow at the University of Oxford, England where he received extensive training in clinical trials. Dr. Carson was a member of Clinical Trials Review Committee at the National Heart, Lung and Blood Institutes and served as Chair during his 5th year.
The focus of Dr. Carson’s research is on determining the indications for red blood cell transfusion. He was study chair of the FOCUS trial which was published in the New England Journal of Medicine and the Lancet and was recognized as one of the 34 key research findings published in 2012 funded by the NIH. He is the Study Chair of the NIH funded MINT trial which will enroll 3500 patients with acute myocardial infarction evaluating transfusion thresholds. He was the Chair of the AABB Clinical Guidelines on Red Blood Cell Transfusion and recently published an invited review on Red Blood Cell Transfusion in the New England Journal of Medicine.
Chief, Division of Transfusion Medicine
The Children's Hospital of Philadelphia
Associate Professor, Pediatrics
Perelman School of Medicine at the University of Pennsylvania
“I feel tremendous gratitude for the NBF grant which provided critical support during my early career in transfusion medicine which was essential for establishing my research laboratory and translational program to improve transfusion therapy for patients with sickle cell disease.”
NBF Grant Year: 2013
NBF Research Project Title: “Red blood cell generation from human induced pluripotent stem cells: a new tool for transfusion medicine.”
NBF Grant Led To: A project generating novel red blood cell reagents from induced pluripotent stem cells engineered to express combinations of blood group antigens that are rare or never found. We anticipate that these customized induced pluripotent stem cell-derived red cells will be a product on the shelves of blood banks, and will allow rapid identification of antibodies common among patients with sickle cell disease leading to quicker, more efficient matching of blood.
Dr. Stella Chou is Division Chief of Transfusion Medicine at the Children's Hospital of Philadelphia and an Associate Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. She practices Pediatric Hematology and Transfusion Medicine at The Children’s Hospital of Philadelphia with a particular interest in patients with Sickle Cell Disease. Her work has demonstrated that inheritance of variant or altered blood group antigens in patients with Sickle Cell Disease contributes to their high rate of red cell antibody formation. Her research interests include improving antibody identification and blood antigen matching for patients using molecular tools. Her research laboratory uses induced pluripotent stem cells (iPSCs) and primary human cells to model blood diseases and study their underlying pathophysiology. Ongoing work focuses on creating customized iPSCs with rare blood group antigen combinations as renewable sources of RBC reagents to improve antibody identification and donor RBC matching. Since transfusion therapy remains a critical treatment for hemoglobinopathies, her goal is to identify new approaches to minimize red blood cell alloimmunization, reduce complications and improve therapy.
Yale University School of Medicine
Professor, Departments of Laboratory Medicine, Cell Biology and Pathology
Yale Stem Cell Center
Clinical Cell Processing Laboratory
“The research award that I received from the National Blood Foundation (NBF) was very important to me and came at a critical time early in my career. The ability to receive funding and the amount of money received were both key in my now having uninterrupted NIH funding and multiple exciting discoveries on the transcriptional regulation of early hematopoiesis.”
NBF Grant Year: 1997
NBF Research Project Title: “Regulation of CD34 Expression During Hematopoiesis.”
NBF Grant Led To: Discoveries regarding the basic mechanisms underlying transcriptional regulation in hematopoietic stem and progenitor cells. Now with improved technologies including high throughput assays, single cell assays and long-term time-lapse microscopy, we perform multicomponent studies interweaving cell biology, transcriptional regulation and epigenetic regulation. The discoveries we make today may lead to improved therapeutic strategies for promoting platelet and red blood cell production in vitro and/or in vivo.
Dr. Krause is a physician scientist at Yale University, where her responsibilities are centered in four major environments. As Associate Director of the Yale Stem Cell Center, she has built a highly successful stem cell research coalition at Yale. As PI of her independent research laboratory, she has established a national and international reputation as a leader in studies of adult stem cells and leukemia with discoveries on the transcriptional regulation of hematopoiesis with an emphasis on megakaryocyte fate specification and maturation as well as platelet function. Recent discoveries include isolation and single cell analysis of bipotent primary human megakaryocytic-erythroid progenitors (MEP) include single cell RNA sequencing and single cell timelapse microscopy allowing visualization of single cells as they undergo cell division and fate decisions. As Director of the Yale Cooperative Center of Excellence in Molecular Hematology, she has established a core facility that serves hematology researchers throughout the country. As Medical Director of the clinical Stem Cell Transplantation Laboratory, she oversees clinical cell processing for the bone marrow transplantation program as well as the Advanced Cell Therapy GMP laboratory for clinical trials in cell therapy.
Professor of Pediatrics
Director, Hoxworth Blood Center
Leader, Stem Cell Group and Translational Core Laboratories
Director, Cancer & Blood Diseases Institute of Cincinnati Children's Hospital Medical Center
University of Cincinnati Academic Health Center
“The National Blood Foundation was a crucial step in my career since it provided me with the first source of extramural funding to support my research project in 2005. As a result, I was able to generate data that cemented the fundamentals of my research endeavors.”
NBF Grant Year: 2005
NBF Research Project Title: “Mobilization of Hematopoietic Stem Cells by Reversible Inhibition of Rac-Type Rho GTPases: Demonstration of Proof-of-Concept for Future Clinical Applications.”
Jose Cancelas, MD, PhD is Professor of Pediatrics and the Director of Hoxworth Blood Center. He is also Leader of the Stem Cell Group and Translational Core Laboratories and Director of the Cancer & Blood Diseases Institute of Cincinnati Children's Hospital Medical Center. He holds the Beatrice C. Lampkin Endowment for Stem Cell and Hematotherapy Research. He has published over 150 peer-reviewed manuscripts in the areas of hematopoiesis and transfusion/cell therapies. His laboratory is funded by the NIH, US DoD and different private foundations and corporations. His basic biology laboratory has contributed to the elucidation of the cellular and molecular mechanisms of hematopoietic stem cell and granulocyte progenitor activity in health and leukemia and provided the basis for understanding the physiological cell-autonomous and microenvironment/cytokine dependent mechanisms that control hematopoietic stem cell-activity in the bone-marrow microenvironment. His translational work is focused on the development of new blood and cell therapy products with augmented efficacy and/or safety profiles in the areas of transfusion, stem cell transplantation and immunotherapy. His clinical group has optimized methods of progenitor and granulocyte collection for transfusion in neutropenic patients and developed or validated novel methods to preserve and store T lymphocytes, red cells and platelets.
Professor, Department of Pathology
University of Michigan
Associate Medical Director of Transfusion Medicine
Medical Director for the Cellular Therapy and Immunohematology Reference Laboratories
“The NBF was an important step in my early career as a young faculty member transitioning into academic medicine. It provided a foundation for subsequent clinical and translation studies during my career in the areas of immunohematology and bone marrow transplantation support.”
NBF Grant Year: 2003
NBF Research Project Title: ““Molecular Analysis of Globo- and Lacto-Family Glycosyltransferases: Molecular Etiology of the LKE-Negative and LKE-Weak Phenotypes.”
Laura Cooling, MD, MS is a Professor in the Department of Pathology at the University of Michigan. She is an Associate Medical Director of Transfusion Medicine and serves as the Medical Director for the Cellular Therapy and Immunohematology Reference Laboratories. She has served on multiple AABB committees including the Education Committee (Chair), Annual Meeting Education Program Unit (Chair), Continuing Education Advisory Committee, Abstract Selection Committee, Strategic Abstract Working Group (Chair), National Blood Foundation grant review, Transfusion Medicine Scientific Section Coordinating Committee, and Standards Committee. She has also participated in several AABB publications including the Technical Manual and Blood Transfusion Therapy Physician’s Handbook. In addition to AABB, she is active in ASFA educational and research activities and was recently awarded the 2016 ASFA Lecturer award. She has authored or co-authored nearly 200 articles, book chapters and abstracts in the field of transfusion medicine, particularly in the areas of immunohematology and stem cell collection. Recent and ongoing studies include completion of the platelet glycolipidome, including inherent donor-specific variation; a large comprehensive review of Blood Groups in Host Susceptibility and Infection for the American Society of Microbiology; pre-clinical studies in therapeutic management of CAIHA; and several papers in pediatric and adult stem cell transplantation.
Medical Director, Transfusion Medicine Services
Chief, Division of Laboratory Medicine, and Professor, Department of Pathology
University of Virginia
“NBF was the very first grant for my nascent research lab as an independent Principal Investigator and was instrumental in launching our early research efforts focusing on cytokines in transfusion biology, tolerance, and autoimmunity. The NBF holds a special place in my heart.”
NBF Grant Year: 2000
NBF Research Project Title: “T Cell Cytokine Secretion in a Murine Model of Transfusion-associated ImmunoModulation (TRIM).”
Jim Gorham received the MD PhD degrees from New York University in 1992 and completed residency training in Laboratory Medicine as well as post-doctoral research experience in Immunology at Washington University. He joined the faculty at Dartmouth Medical School in 1998 and began his independent research lab focusing on the role of cytokines in modulating immune responses, garnering the NBF grant as his first extramural funding. While at Dartmouth, Dr. Gorham completed a Fellowship in Transfusion Medicine. He was recruited to UVA in 2015, where he serves as Chief of the Division of Laboratory Medicine, and Medical Director of Transfusion Medicine Services. Dr. Gorham has made research contributions in a variety of fields, including not only Transfusion Medicine, but also Immunology, Hepatology, and Genetics. Dr. Gorham has published widely, held several NIH and non-NIH grants, served on multiple NIH study sections, and been a consistently loyal grant reviewer for the NBF for many years.
Professor of Laboratory Medicine and Pediatrics
Medical Director of the Apheresis Service
Associate Medical Director of the Transfusion Medicine Service
“Early career funding by the National Blood Foundation was instrumental in allowing Dr. Hendrickson the time and resources to develop her red blood alloimmunization research ideas. The NBF grant that Dr. Hendrickson was awarded also provided her with confidence that her research ideas were worthy of exploration.”
NBF Grant Year: 2006
NBF Research Project Title: “Effect of Host Inflammation On Alloimmunization to RBC Transfusion.”
Jeanne Hendrickson, MD, is a Professor of Laboratory Medicine and Pediatrics at Yale University, the Medical Director of the Apheresis Service, and the Associate Medical Director of the Transfusion Service. Trained in Pediatric Hematology/Oncology and Transfusion Medicine, Dr. Hendrickson’s clinical interests include optimizing transfusion support patients of all ages. Her translational research interests revolve around understanding factors that influence red blood cell alloimmunization in transfusion and pregnancy settings. Her long-term goals include developing strategies to prevent the formation of RBC alloantibodies in patients at highest risk of this complication, as well as developing therapies to mitigate the dangers of existing RBC alloantibodies.
Executive Vice-Chair of Laboratory Medicine and Professor
Department of Pathology & Cell Biology
“I received an NBF grant soon after arriving at Columbia University. I had decided to take the risky step of radically changing my research focus to use mouse models to study poorly understood issues in transfusion medicine, such as the mechanisms underlying hemolytic transfusion reactions. This funding was critically important in allowing us to change our focus and succeed in a new area.”
NBF Grant Year: 2003
NBF Research Project Title: “Hemolytic Transfusion Reactions: A Transgenic Mouse Model.”
Before arriving at Columbia University in 2003, Dr. Spitalnik was a faculty member at the University of Pennsylvania (1985-1998) and the University of Rochester (1998-2003). He received his M.D. from the University of Chicago, pursued residency training in anatomic and clinical pathology at the University of Rochester, and research training in molecular biology and glycobiology at the University of Rochester and the National Institutes of Health, respectively.
Dr. Spitalnik has held committee and leadership positions in various organizations, including the AABB (currently a member of the Board of Directors), the Academy of Clinical Laboratory Physicians and Scientists, and the American Society of Hematology. He has published over 230 papers and is on the editorial boards of Transfusion and Transfusion Medicine Reviews. In addition, he has served as a member and chair of multiple study sections for the National Institutes of Health.
Dr. Spitalnik’s initial research in glycobiology often used human blood group antigens as models. Over the last 20 years, he has studied the consequences of red blood cell clearance following transfusion, during hemolytic transfusion reactions, in G6PD-deficiency, and in malaria. He is currently supported by grants from the National Institutes of Health.
Executive Director of Research
Lindsley F. Kimball Research Institute (LFKRI)
New York Blood Center
“The NBF grant support allowed me to pursue a new exciting research direction in transfusion medicine and to secure my first R01 and American Heart Association grants. I am forever grateful to the NBF for providing me with the crucial support to jumpstart my career in transfusion medicine.”
NBF Grant Year: 2000
NBF Research Project Title: “Recombinant Antigens as Tools for Identification of Alloantibodies in Patients' Sera.”
Karina Yazdanbakhsh, PhD is the Head of Laboratory and Member of the Lindsley F. Kimball Research Institute (LFKRI) of the New York Blood Center. The focus of her research is characterization of cellular immune responses against blood components in the context of alloimmunity and autoimmunity. Supported by funding from NIH/NHLBI, she has been investigating the immunoregulatory networks that control development of antibodies (alloimmunization) against transfused red cells in patients with sickle cell anemia. By better understanding these processes, the goal is to not only identify immune biomarkers of alloimmunization to predict antibody responders but also to develop targeted therapies to prevent alloimmunization in this patient population. She also studies cellular and molecular aspects of platelet autoimmunity in patients with immune thrombocytopenia (ITP) with the goal of developing new and improved treatments. Current research focus funded by NIH/NHLBI is on identifying immunological signatures of ITP drug response.
Vice President, Research and Scientific Programs
Director and Senior Investigator
Vitalant Research Institute
“The NBF funding was central to completion of my PhD, and has been a key in transitioning to an academic focus that provides a strong bridge between product development, academic research, education and delivery of clinical care. This has strengthened my contributions to the safe and efficacious care of patients.”
NBF Grant Year: 2002
NBF Research Project Title: “Human Cytomegalovirus (HCMV) Reactivation – Human Exposure Model and Mechanism D.”
Dr. Dumont received an MBA from the University of Phoenix and a PhD in clinical sciences from the University of Colorado Health Sciences Center in Denver. He is establishing and expanding VRI in Denver with a translational and product development mission. Dr. Dumont spent 27 years at GAMBRO BCT in various technical capacities where he developed and lead the PASSPORT study. He has been actively involved with the Biomedical Excellence for Safer Transfusion Collaborative (BEST) for 23 years, and is a past Chair of BEST. Dr. Dumont has been an invited speaker at meetings of the FDA Blood Product Advisory Committee, the US Department of Health and Human Services Advisory Committee on Blood Safety and Availability, the Paul-Ehrlich-Institute, and various national and international congresses. His current interests are in platelet and red blood cell physiology, cryopreservation of platelets, the red blood cell storage lesion, in vivo cell survival kinetics, and clinical outcomes in transfusion medicine.
Division Hematology & Transfusion Medicine
Department of Laboratory Medicine
Clinical Immunology and Transfusion Medicine
Office of Medical Services
“My NBF grant permitted me to establish myself in a new country and gave stability to my post-doctoral employment. Those early results led to further funding from other local sources, and to the discovery of a novel erythrocyte protein. NBF grants are an enormously important source of research funding in Transfusion Medicine and Cellular Therapy.”
NBF Grant Year: 2006
NBF Research Project Title: “Characterization of the Vel Blood Group System.”
Dr. Jill Storry is an Associate Professor at the Division of Haematology & Transfusion Medicine, Department of Laboratory Medicine, Lund University (LU), Sweden, and also responsible for the Immunohematology laboratories within the Department of Clinical Immunology and Transfusion Medicine, Laboratory Medicine, Lund.
Primary areas of interest are the study of human blood group systems, both from a clinical perspective in the provision of providing blood to alloimmunised patients and from the perspective of human polymorphism, and its role in health and disease. Her research focus is the investigation and characterisation of erythrocyte membrane glycoproteins carrying blood group polymorphisms, their function and interaction with pathogens, e.g. malarial parasites.
Jill was inaugurated to the National Blood Foundation’s Hall of Fame in 2015 for the characterisation of the Vel blood group system. Other awards include the Margaret Kenwright and Race & Sanger Awards (British Blood Transfusion Society), as well as the aaBB Sally Frank Award. She has authored over 80 original papers, reviews and text books related to serological and molecular aspects of blood groups, and given over 100 talks at international and national conferences and courses.
Jill is a member of the Editorial Boards of Transfusion Medicine Reviews, Transfusion and Immunohematology, Section Editor for Vox Sanguinis and a peer reviewer for these and other scientific journals. She is a member of the ISBT Working Parties on Red Cell Immunogenetics and Red Cell Nomenclature, and Rare Donors.
University of Virginia
“My NBF award came at a crucial time, early in my career, when it was unclear in what direction my lab would develop. The support was indispensable in allowing me to develop a mature research program, focused on transfusion biology, which has been the basis of my research career.”
NBF Grant Year: 2004
NBF Research Project Title: “Selective Induction of Allotolerance in Bone Marrow Transplantation.”
James Zimring obtained a B.S. in chemistry, a Ph.D. in Immunology, and an M.D., all from Emory University; he is board certified in Clinical Pathology. Dr. Zimring was an Assistant and then tenured Associate Professor at Emory where he built a basic science program focusing on immunology of transfused RBCs and Platelets. In 2012, Dr. Zimring joined the BloodworksNW Research Institute in Seattle where he ran an NIH funded laboratory. Currently, Dr. Zimring is a professor of pathology at the University of Virginia, has published over 120 research articles in his field of study, is an active participant in NIH grant review and is on the editorial board of the journals Transfusion and Transfusion Medicine Review.
Dr. Zimring has received the David B. Pall award (now the Jack Latham Memorial Award for Innovative Research) from AABB, the Jean Julliard award from ISBT, and the Ellis Benson award from ACLPS. He received the Herbert Perkins Scientific Lectureship and Award, and delivered the Claes F. Högman Lectureship. He is also an elected member the American Society for Clinical Investigation. Dr. Zimring is a dedicated teacher and in 2011 received the Crystal Apple Award from Emory University for “Excellence in Graduate Education and Instruction”.
Happily retired, sailing the seven seas…
Former President and Chief Executive Officer
AABB Past President
“The support I received from NBF was critical in allowing me to start my career in radiolabeling and component improvement.”
NBF Grant Year: 1985
NBF Research Project Title: “Use of Indium111 as a Red Cell Label in Survival Studies.”
A graduate of the University of Michigan, Dr. AuBuchon trained at the National Institutes of Health before serving in blood center and national headquarters positions of the American Red Cross Blood Services. Before joining Bloodworks in Seattle, he spent 18 years at Dartmouth-Hitchcock Medical Center as the Medical Director of the Blood Bank and Transfusion Service and then as the E. Elizabeth French Professor and Chair of Pathology and Professor of Medicine. His research has paralleled a long-standing interest in improving component collection and storage, documenting their effectiveness through radiolabeling. He also has been active in developing processes to improve recipient safety through identification of the benefits and costs of new safety initiatives.
Dr. AuBuchon served as a member of the Advisory Committee on Blood Safety and Availability and has chaired the BEST Collaborative. He was elected a Fellow of the Royal College of Physicians of Edinburgh and is a Past President of the AABB.
Vitalant Research Institute
Senior Vice President
Professor of Laboratory Medicine
“Although an investigator on grants prior to my NBF-grant in 1992, this was my first PI-status grant. The NBF grant led to a publication in Blood and development of the Viral Activation in Transfusion Study. Over the subsequent decades I have led dozens of similar studies with BSRI as the Central Laboratory.”
NBF Grant Year: 1992
NBF Research Project Title: “Impact of Homologous Blood Transfusion on HIV Replication and Disease in Vivo.”
Dr. Michael Busch earned his MD and PhD degrees at USC followed by residency training in Pathology, Laboratory Medicine and Transfusion Medicine at UCSF. He is the founding Director of Vitalant Research Institute (VRI) in San Francisco and Senior Vice President for Research and Scientific Affairs at Vitalant, a national network of non-profit blood centers and donor testing laboratories. Dr. Busch’s major research interests include: 1) epidemiology, pathogenesis and laboratory diagnosis and monitoring of transfusion-transmitted viral infections, including HIV-1/2, HTLV-I/II, HBV and HCV, as well as blood safety implications of new and emerging infectious diseases (e.g., WNV, Dengue viruses, chikungunya virus, T. cruzi, babesia, ZIKV); 2) development and implementation of improved blood donor screening assays/algorithms, with particular focus on enhanced serological assays, nucleic acid amplification technologies and pathogen reduction technologies; 3) mechanisms and prevention of immunological consequences of transfusions, including microchimerism, graft-vs-host disease, transfusion-related acute lung injury and alloimmunization; and 4) mechanisms of HIV latency and development and validation of novel assays to quantify HIV reservoirs in ART-suppressed subjects in the context of cure research interventions; and application of genetic and other “omics” technologies to understand and enhance the efficacy of transfusions. Dr. Busch has published ~550 peer-reviewed original scientific articles and over 150 review articles, editorials and book chapters.
Blood Transfusion Service
Massachusetts General Hospital
“Participation in the NBF-- as an applicant, an awardee, a reviewer of grant applications, and as a financial contributor—has built strong and positive relationships during my career in academic Transfusion Medicine. I look at recent and current NBF awardees and I am extremely proud of their scientific achievements and their investigative enthusiasm. NBF is one of the best parts of our Profession. Congratulations and many thanks to those who make the NBF stronger each year.”
NBF Grant Year: 1994
NBF Research Project Title: “Transient Microchimerism Following Allogeneic Blood Transfusion.”
Dr. Dzik’s clinical interests are in transfusion medicine, hemostasis, and non-cancer hematology. He is a founding member of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. In 2002, Dr. Dzik led a large, international, multicenter BEST Study focused on blood grouping errors due to miscollected samples. A previous international study with this group focused on standardization of CD34+ cell counting during progenitor cell collections. Dr. Dzik's research interests include management of the coagulopathy of liver disease, clinical use of blood components, biologic consequences of recipient exposure to allogeneic donor leukocytes, and patient safety in transfusion. Studies are currently underway on oxygen delivery to children with profound anemia due to malaria.
Dr. Dzik is devoted to mentoring the next generation of leaders in academic Transfusion Medicine. In recent years, he has had the great honor to advise on research projects undertaken by recent NBF awardees, ranging from the importance of ABO blood groups in the pathophysiology of severe malaria to the role of protein C in purpura fulminans. Most recently, working with former NBF awardees and colleagues he has done fundamental clinical research on the delivery of oxygen to tissues by Red Blood Cells after transfusion.
President and CEO
New York Blood Center
Professor, Department of Medicine
Weill Cornell Medical College
New York, New York
AABB Past President
“The value of the NBF grant to me was substantial. It was seed funding at a point in my career when I would not have been able to get major, investigator initiated grants. It was peer reviewed at a very good and high level, allowing me to learn the process. These set the stage for me to get R01 and even P01- level funding. Through the NBF grant process, I was also able to meet other investigators and network in a way that supported my career development.”
NBF Grant Year: 1991
NBF Research Project Title: “Peripheral Blood Stem Cells for Allogeneic Transplantation: Development of an Animal Model-Initial Phase Investigations.”
Christopher D. Hillyer, MD, is President and CEO of New York Blood Center and Professor, Department of Medicine, Weill Cornell Medical College, NY, NY. Previously, he was the tenured, endowed Distinguished Service Professor, Department of Pathology and Laboratory Medicine, Emory University School of Medicine and served as director of the Emory Center for Transfusion and Cellular Therapies with responsibility for all aspects of clinical and academic transfusion medicine at Emory's seven principal hospitals.
Dr. Hillyer is an editor of eleven textbooks in transfusion medicine including the 16-18th editions of the AABB Technical Manual, author of over 150 articles pertaining to transfusion, HIV, and herpes viruses, most notably cytomegalovirus. Nationally recognized as an expert in hematology and blood transfusion, Dr. Hillyer is also a past-president, board of directors of AABB and a former trustee of the National Blood Foundation. Dr. Hillyer has been awarded many millions of dollars in research funding from the National Institutes of Health, the Centers for Disease Control and Prevention and other agencies. He is an associate editor of Transfusion and serves on several other editorial boards.
Dr. Hillyer is board certified in transfusion medicine, hematology, medical oncology and internal medicine. He received his BS from Trinity College, and his MD from the University of Rochester School of Medicine, with postgraduate training and fellowships in hematology-oncology, transfusion medicine and bone marrow transplantation at Tufts-New England Medical Center.
Senior Vice President and Chief Medical Officer
Verax Biomedical Inc.
AABB Past President
“The National Blood Foundation Grant I received played a key role in the transfusion medicine research program at the University of Virginia and in my career development. This award allowed us to study the relationship of platelet morphology to platelet recovery and survival and to learn the techniques required to radiolabel platelets and to perform these studies. We subsequently applied this knowledge to other research.”
NBF Grant Year: 1986
NBF Research Project Title: “Correlation of Non-invasive Assessment of Platelet Morphology with Platelet Recovery and Survival.”
Dr. Mintz currently serves as Senior Vice President and Chief Medical Officer of Verax Biomedical Inc. Prior to this appointment, he was the Director, Division of Hematology Clinical Review in the Office of Blood Research and Review at the Center for Biologics Evaluation and Research, Food and Drug Administration.
Before joining the FDA in 2011, Dr. Mintz was a tenured Professor of Pathology and Medicine at the University of Virginia (UVA) Health System serving as Vice Chair of Pathology and Chief of the Division of Clinical Pathology and as Medical Director of the Clinical Laboratories and Transfusion Medicine Services. While at UVA, Dr. Mintz created the fellowship in transfusion medicine that has contributed to the career development of more than 25 early career physicians.
Dr. Mintz served on the AABB Board of Directors for nine years including a term as President from 2004-2005 and chaired and served on many AABB Committees. As AABB President, he conceived and assured the development of the now published AABB guidelines for red cell, platelet and plasma transfusions. He was also instrumental in creating the position of AABB Senior Medical Advisor, expanding the Association’s activities into biotherapies, and for achieving deemed status from the Joint Commission.
Dr. Mintz received the AABB’s John Elliott Memorial Award in 2015. Previously, he was also the recipient of a Transfusion Medicine Academic Award from the NHLBI and a Deans' Award for Teaching Excellence from the University of Virginia School of Medicine. Dr. Mintz has authored or co-authored more than 100 peer-reviewed papers related to transfusion medicine, served as the sole editor of the first three editions of the textbook Transfusion Therapy: Clinical Principles and Practice, and has been the principal investigator for many clinical and device trials.
Retired and enjoying a budding career as a sommelier…
Formerly Scientific Director, Immunohematology Center
Grifols Diagnostic Solutions Inc.
“My NBF grant allowed me to obtain the experience with molecular techniques as applied to blood groups that I needed to become a leader in the field of molecular immunohematology and become an advocate for the use of blood group genotyping in patient care.”
NBF Grant Year: 1992
NBF Research Project Title: “Determination and Localization of Human Blood Group Polymorphisms on Complement Receptor One (CR1).”
Following post-doctoral work at Washington University School of Medicine, an NBF grant to Dr. Moulds funded her ongoing research on complement receptor type one (CR1), its polymorphisms and relation to disease. Thru these studies she identified the Knops antigens on CR1 and showed that CR1 played a role in the rosetting of. P. falciparum infected cells to uninfected red cells. Clinical data which emerged from her studies in Mali also showed that blood group O red cells had reduced rosetting and this correlated with less severe malaria. The extensive experience with molecular techniques acquired during her research led Joann to a position at LifeShare Blood Centers where she became involved in the newly evolving field of blood group genotyping. Accordingly, Dr. Moulds served as chairperson of the AABB program unit that produced the first Standards for Molecular Testing for Red Cells, Platelet and Neutrophil Antigens in 2008. Dr. Moulds left LifeShare in 2014 to become Scientific Director of the new Immunohematology Center at Grifols Diagnostic Solutions where her group continues to investigate the molecular aspects of blood groups and relates them to serology.
Former Senior Director
American Rare Donor Program
Immunohematology Journal of Blood Group Serology and Molecular Genetics
American Red Cross
Former Adjunct Assistant Professor
Division of Transfusion Medicine and Therapeutic Pathology
University of Pennsylvania
“AABB’s National Blood Foundation grant was the first grant I applied for and received which led to a subsequent publication reporting use of the Monocyte Monolayer Assay. These early research years as a PI on the AABB NBF Grant were formative and laid the foundation for my continuing research, presentations, publications, and review roles. It reinforced the importance of learning and teaching others. The NBF grant, becoming an NBF Scholar and inaugural inductee to the NBF Hall of Fame is a continuing source of pride along with having the MMA be used to predict transfused RBC survival of incompatible red blood cells over 35 years later.”
NBF Grant Year: 1989
NBF Research Project Title: “A comparison of the Efficiency of the Monocyte Monolayer Assay IgG Subclassing, OD450 Amniotic Fluid, and Ultrasonography in Prediction of the Severity of Hemolytic Disease of the Newborn.”
As Senior Director for National Laboratories for the American Red Cross and throughout her career, Ms. Nance provided leadership to the American Rare Donor Program, HLA Laboratories, Immunohematology Reference Laboratories, Molecular Laboratory, National Reference Laboratories for Blood Group Serology, Neutrophils, and Specialized Testing, as well as the Red Cross Specialist in Blood Banking Program. She was an Adjunct Assistant Professor at the University of Pennsylvania, Division of Transfusion Medicine & Therapeutic Pathology Department of Pathology and Laboratory Medicine. She has a master’s degree in Pathology from the University of Maryland and received her SBB from the Johns Hopkins Medical Institutions.
Ms. Nance has held leadership positions in the AABB, ASCP, ICII, and ISBT. Among other roles, she led the Scientific Program Committee that started the “tracks” for which she received a President’s Award and was on four nominating committees for AABB and ASCP. She chaired the ISBT Working Party on Rare Donors, conceptualized the new ISBT Working Party on Immunohematology and was the first Chair. She initiated and led the Case Studies Section. She managed Fellowship Rotations for the University of Pennsylvania and Thomas Jefferson University. She was Editor-in-Chief of the Immunohematology Journal of Blood Group Serology and Molecular Genetics, is on the Editorial Board and serves as a reviewer for Transfusion and other journals. She has authored or co-authored over 45 papers, 250 abstracts and edited 9 books.
The Monocyte Monolayer Assay that she developed has been used since 1987 for the prediction of survival of transfused incompatible red cells and staff from twelve countries have trained in her laboratory. She was the inventor of the “PEG” test.
She has been honored for her contributions to Transfusion Medicine with awards from AABB, AIMS, ASCP, Maryland Society of Medical Technologists, Michigan Association of Blood Banks, New York Supervisors, Red Cross, Singapore Ministry of Health, and University of Texas Medical Branch. She was named to the ASCP Hall of Fame with a Mastership Award and was featured in the White Coats section of AABB News.
Former Director of Immunohematology and Head Immunochemistry
New York Blood Center
“The NBF is a very valuable stepping-stone for researchers. It follows the NIH format and gave me experience in grant writing.”
NBF Grant Year: 1993
NBF Research Project Title: “Studies on the Surface Markets of Glycophorin in Molecules in Human Red Blood Cells.”
Dr. Reid was trained as a medical technologist in Hematology, Blood Transfusion, and Blood Group Serology at the North East Metropolitan Blood Transfusion Service. She later obtained a MSc in Clinical Science, and a PhD in Biochemistry. She has worked in immunohematology reference laboratories in the UK and USA.
Marion acquired an extensive serological, biochemical, and molecular knowledge of blood groups and their application to clinical practice and human genetics. She has published over 400 peer-reviewed articles, reviews and chapters. A book she co-authored, the Blood Group Antigen FactsBook, is a well-used and respected reference in immunohematology laboratories. Marion has served on numerous committees and editorial boards, was a reviewer for several journals, received several grants, and holds a patent.
A recognized expert she has received numerous awards, including the Ivor Dunsford Award, the Sally Frank Award; the International Woman in Transfusion Award, the Emily Cooley Award, the James Blundell Award, and an honorary Doctorate in Science from the University of Plymouth. Marion willingly shared her knowledge with others—from peers to children. She is now retired and living in England. She is currently co-authoring a book on the history of blood group and one about blood for children.
Emory University School of Medicine
“Although I received an NBF grant in 1998, when NIH funding was relatively abundant, the NBF award was absolutely critical for jump-starting my transfusion medicine research career and laying the groundwork for my later investigations. In today’s more challenging NIH funding climate, NBF awards are more important than ever for developing the next generation of transfusion medicine investigators.”
NBF Grant Year: 1998
NBF Research Project Title: “The Role of Leukocytes in Transfusion-Transmitted Cytomegalovirus (TT-CMV) Infection: Development of an Animal Model.”
Dr. Roback is a Professor (tenured) in the Department of Pathology and Laboratory Medicine of the Emory University School of Medicine. His administrative appointments include Director of the Center for Transfusion and Cellular Therapies, Medical Director of the Emory University Hospital and Emory University Hospital-Midtown Blood Banks, and Vice-Chair of the Section of Clinical Pathology and Laboratory Medicine, and Medical Director of Emory Medical Laboratories. His research interests include development of novel technologies for blood typing and compatibility testing, and elucidating the biochemical and physiological effects of RBC storage on cell functionality and recipient outcomes.
In addition to the critical early funding Dr. Roback received from NBF, his work has also been funded by NIH/NHLBI through 2 P01 Program Project awards (PI), 6 R01 grants (3 as PI), and 7 STTR small business awards (6 as PI).
He has published 91 peer-reviewed papers, 27 review articles/editorials, 24 book chapters, and has 8 issued patents. Dr. Roback is a member of the Editorial Board of Transfusion Medicine Reviews, past-Editor of the AABB Technical Manual, and past-Chair of the AABB Clinical Transfusion Medicine Committee.
Professor of Pediatrics and Surgery
School of Medicine
University of Colorado Denver
Senior Independent Investigator
Bonfils Blood Center
“The NBF was the first organization to take my data seriously and gave me working capital when no one else would. This has led to consistent extramural funding and a rewarding clinical and research career. I will be forever indebted.”
NBF Grant Year: 1998
NBF Research Project Title: “The Pathophysiology of Transfusion Related Acute Lung Injury (TRALI) in an Animal Model and In Vitro Investigation of Endothelium as an Active Participant.”
Dr. Silliman’s basic research interests include inflammation and innate immunity, receptor-mediated signaling in neutrophils and vascular endothelium, lipid biochemistry, and Transfusion Medicine with emphasis on transfusion-related acute lung injury (TRALI) and resuscitation following injury. His clinical interests include the etiology of the acute chest syndrome in children with sickle cell anemia and the role of intermediate altitude on children with sickle cell anemia and its role in coagulation with specific regard to venous thromboembolic formation. Dr. Silliman has published >240 papers in peer-reviewed journals, has >300 presentations at national and international meetings. He has trained >40 physicians in basic science and translational research. Dr. Silliman has been fortunate to have received >20 years of extramural funding. He serves as a reviewer for ~20 journals, is a member of the Editorial board of Blood, sits on the Scientific Committee for Transfusion Medicine for the American Society of Hematology National Meeting, and is the Transfusion Medicine Editor for HemOnc Today.
Professor Laboratory Medicine and Pathology
Yale Medical School
Chair, Yale COI Committee
Vice-Chair, DSMB, Yale Cancer Center
Attending, Blood Bank YNHH
Director, Blood Bank Bridgeport Hospital
Co-Director Tissue Programs -Yale-New Haven & Bridgeport
Yale-New Haven Hospital
AABB Past President
“The NBF provided me with funding to start my research in the field of blood filtration. That seed grant grew into a major research effort that afforded me the opportunity to publish papers, participate in local and national research symposia and be recognized as a useful committee member and advisor to National Organizations and Federal Agencies. That small grant of $5,200 paid large dividends and formed the foundation of my career in Transfusion Medicine.”
NBF Grant Year: 1986
NBF Research Project Title: “Calcium-Dependent Proteolysis of Actin During Storage of Platelet Concentrates.”
Edward L. Snyder, MD, FACP, graduated from NY Medical College. He was an Internal Medicine Resident and a Hematology Fellow at Montefiore Hospital in the Bronx, NY. At Montefiore, he also completed a Fellowship in Transfusion Medicine. Dr. Snyder is currently Professor of Laboratory Medicine at Yale University Medical School and an attending blood bank physician at Yale-New Haven Hospital. He is also Chairman of the Yale University Conflict of Interest Committee, Vice-Chair of the Yale Cancer Center Data Safety Monitoring Board, and Chair of the Yale Cancer Center Membership Committee. Dr. Snyder is ABIM board certified in Internal Medicine and Hematology and ABP certified in Transfusion Medicine.
He was President of the AABB from 1997-1998 and Chairman of the NMDP BOD from 2009-2010. Dr. Snyder has served on numerous governmental FDA and NIH advisory panels, most recently on NHLBI R34 and K23 Study Sections. Dr. Snyder is an Associate Editor for Transfusion, and has over 220 publications in the field of Transfusion Medicine. He is a Co-Editor of several books in the field of Transfusion Medicine and Cell Therapy. His active areas of research/clinical interest include Pathogen Reduction, stem cell mobilization and Apheresis Clinical trials.
Executive Scientific Director of Immunohematology and Genomics
New York Blood Center
“The NBF grant brought my research career back to my first love – the field of transfusion medicine -- and the chance to contribute to improve transfusion therapy through genomics.”
NBF Grant Year: 1999
NBF Research Project Title: “Deciphering the Function of the Rh Proteins.”
Currently Dr. Westhoff leads the New York Blood Center Enterprise Immunohematology and Genomics reference laboratories including the National Center for Blood Group Genomics specializing in complex antibody identification and the use of genomics to find compatible donors for patients with transfusion complications. As an expert in the Rh system, her clinical focus is on improved matching of donors with patients who have SCD and Thalassemia using genomics, funded by an Innovations in Clinical Research Award from the Doris Duke Foundation. Her research focus centers on the production of rare RBCs in culture for reagents, as a first step to production of RBCs for transfusion, funded by NIH.
She has published over 100 scientific papers and authored numerous book chapters. She is associate editor for the Immunohematology-Genomics section of Transfusion, a past editor of the AABB technical manual, and a reviewer for numerous journals. She has served on many AABB committees including the AABB board of directors, and as chair of the SSCC and the National Blood Foundation grants review committee, as well as the Transfusion Medicine scientific program committee of the American Society of Hematology.